Chih-Hsin Yang - Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

基本信息

浏览量：265

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 221 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

11P Patritumab deruxtecan (HER3-DXd) in previously treated patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC: Updated safety results from HERTHENA-Lung01

H. Hayashi, Y. Goto, H.A. Yu, P.A. Jänne,J.C-H. Yang, M. Reck, K. Yoh,S-H. Lee, L. Paz-Ares, B. Besse, P. Bironzo,D-W. Kim,

ESMO Open (2024)

引用0浏览0引用

38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) from ALTA-1L

A. Delmonte,M-J. Ahn, S. Ghosh, M.J. Hochmair,T-Y. Yang,J.C-H. Yang,J-Y. Han, K.H. Holmskov,Y. Wu, Y. Wan, M. Lin, J. Kretz,

ESMO Open (2024)

引用0浏览0引用

Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC

H A Yu, C Baik,D-W Kim, M L Johnson, H Hayashi, M Nishio,J C-H Yang, W-C Su, K A Gold, M Koczywas, E F Smit, C E Steuer,

Annals of oncology : official journal of the European Society for Medical Oncology (2024)

引用0浏览0WOS引用

RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)

C. M. Rudin, A. Dowlati, Y. Chen,A. F. Navarro Mendivil,J. C-H. Yang, G. Stojanovic, P. Rich, Z. G. Andric,Y-L. Wu, H. Chen, L. Zhang, S. Yeung,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S129-S130

引用0浏览0WOS引用

Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations

L. Bazhenova,J. Chih-Hsin Yang,M. Wang, P. Mitchell,D. Ross Camidge, J. Fang, W. Nian, C. -H. Chiu,J. Zhou,Y. Zhao, W. -C. Su,T. -Y. Yang,

JOURNAL OF THORACIC ONCOLOGYno. 3 (2023): E3-E3

引用0浏览0引用

30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC

P. Garrido Lopez, N. Girard,B.C. Cho,J. Sabari, A. Spira, R.E. Sanborn, K. Goto,J.C-H. Yang, J. Curtin, X. Lyu, A. He, J. Penton,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S36-S37

引用0浏览0引用

1319MO Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01

M.L. Johnson, P.A. Jänne, Y. Goto, K. Yoh,S-H. Lee, L. Paz-Ares, B. Besse,S. Novello, H. Hayashi,D-W. Kim,T. John, S.C-H. Kao,

Annals of Oncology (2023): S760-S761

引用0浏览0引用

PP01.40 Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L

D Ross Camidge,H. Ryun Kim,M.J. Ahn,James CH. Yang,J.-Y. Han,M.J. Hochmair, K.H. Lee,A. Delmonte,M.R. Garcia Campelo,D.-W. Kim,F. Griesinger,E. Felip,

Journal of Thoracic Oncologyno. 3 (2023): e27-e27

引用0浏览0引用

OA01.07 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations

L. Bazhenova,J. Chih-Hsin Yang,M. Wang, P. Mitchell,D. Ross Camidge, J. Fang, W. Nian,C.-H. Chiu,J. Zhou,Y. Zhao, W.-C. Su,T.-Y. Yang,

Journal of Thoracic Oncology（2023）

引用0浏览0引用

First-line (1L) osimertinib plus platinum-pemetrexed in EGFRmutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results

D. Planchard, A. Poltoratskiy,S-W. Kim,T. M. Kim, N. Yanagitani, H. Kagamu,P-H. Feng, B. Hughes,T-Y. Yang,J. C-H. Yang, C. K. Lee, N. Karaseva,

ANNALS OF ONCOLOGY (2023): S1692-S1693

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn